adsilico Raises £10m for Virtual Patient Technology

Leeds medtech spinout adsilico has raised £10m to expand its AI-powered virtual patient technology for testing medical devices, according to Htworld.

Funding targets virtual patient technology

Htworld reports that adsilico will use the £10m raise to expand its technology. The company’s focus, as described by the publisher, is AI-powered virtual patient technology for testing medical devices.

The funding event centers on a testing application within the medical device sector. Htworld identifies adsilico as a medtech spinout based in Leeds and connects the raise with the expansion of its virtual patient technology.

Reported focus on medical device testing

Virtual patient technology is the stated focus of adsilico’s expansion. According to Htworld, the technology is AI-powered and is used for testing medical devices.

For medical device sales professionals, the reported development concerns a company working on technology intended for the device-testing process. The announcement also places AI-powered virtual patient technology at the center of adsilico’s reported growth plans.

Htworld’s report provides the funding amount, the company’s Leeds medtech spinout status, and the intended use of the raise. It does not provide further detail on the funding participants or the company’s expansion plans.

Key reported details

• adsilico is a Leeds medtech spinout.
• Htworld reports that the company raised £10m.
• The raise is intended to expand AI-powered virtual patient technology.
• The technology is focused on testing medical devices.

What the announcement establishes

The reported event is a £10m funding raise by adsilico. Htworld describes the intended use as expansion of virtual patient technology rather than a broader set of initiatives.

The announcement links the company’s technology directly to medical device testing. For readers tracking medical technology developments, the reported facts are the Leeds spinout’s funding, its AI-powered virtual patient focus, and the stated testing application.